BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Shengbing HuangFrank A Sinicrope

Abstract

Prosurvival Bcl-2 proteins inhibit the mitochondrial and death receptor-mediated apoptotic pathways. Obatoclax is a small-molecule antagonist of the BH3-binding groove of Bcl-2 proteins that may enhance tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity and efficacy. Human pancreatic cancer cell lines were incubated with obatoclax and/or TRAIL and cell viability, Annexin V labeling, caspase cleavage, and cytochrome c release were measured. In drug-treated cell lines, protein-protein interactions were studied by immunoprecipitation. Bax/Bak activation was analyzed using conformation-specific antibodies. Lentiviral short hairpin RNA was used to knockdown Bim, Bid, and apoptosis-inducing factor (AIF) expression. Obatoclax reduced the viability of PANC-1 and BxPC-3 cell lines and synergistically enhanced TRAIL-mediated cytotoxicity. Obatoclax enhanced TRAIL-mediated apoptosis, as shown by Annexin V labeling, which was accompanied by caspase activation (caspase-8, -9, and -3) and cleavage of Bid. Obatoclax potentiated TRAIL-mediated Bax/Bak activation and the release of mitochondrial cytochrome c, Smac, and AIF. Mechanisms underlying the apoptotic effect of obatoclax include displacement of Bak from its sequ...Continue Reading

References

May 2, 1998·The EMBO Journal·C ScaffidiM E Peter
Jan 11, 2000·Molecular and Cellular Biology·R EskesJ C Martinou
Feb 13, 2001·Biochemical and Biophysical Research Communications·S Y SunG S Wu
Nov 25, 2003·Oncogene·Shulin Wang, Wafik S El-Deiry
Mar 5, 2004·Biochimica Et Biophysica Acta·Andrew M PetrosStephen W Fesik
Mar 16, 2004·Cell Death and Differentiation·C CandéG Kroemer
Jun 11, 2004·Annual Review of Biochemistry·Xuejun Jiang, Xiaodong Wang
Nov 5, 2004·The EMBO Journal·Nicola VahsenGuido Kroemer
Dec 24, 2004·The Journal of Biological Chemistry·V Courtney BroaddusGerard I Evan
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frank A SinicropeXi Ming Tang
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
May 28, 2005·The EMBO Journal·Matthew G AnnisDavid W Andrews
Oct 18, 2005·Molecular and Cellular Biology·Yoshinori TakahashiHong-Gang Wang
Apr 28, 2006·The EMBO Journal·Paulina J DlugoszDavid W Andrews
Apr 29, 2006·Cell Death and Differentiation·V LabiA Villunger
Apr 29, 2006·Cell Death and Differentiation·D ZhaiJ C Reed
Jan 20, 2007·The EMBO Journal·Oliver KeppThomas Rudel
Feb 27, 2007·Oncogene·J M Adams, S Cory
Mar 29, 2007·Proceedings of the National Academy of Sciences of the United States of America·Peter E CzabotarPeter M Colman
Nov 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Mai NguyenGordon C Shore

❮ Previous
Next ❯

Citations

Aug 3, 2013·Investigational New Drugs·Kumudha Balakrishnan, Varsha Gandhi
Jan 1, 2010·Cell Death & Disease·F McCoyD A Fennell
Jun 8, 2011·Antioxidants & Redox Signaling·Simone Fulda, Guido Kroemer
Feb 18, 2010·Cancer Research·Rory L SmootGregory J Gores
Mar 4, 2010·Molecular Cancer Therapeutics·Shengbing Huang, Frank A Sinicrope
Dec 17, 2009·World Journal of Gastroenterology : WJG·Bruno-Christian KoehlerHenning Schulze-Bergkamen
Apr 29, 2014·Cell Death and Differentiation·B WangX Deng
Nov 17, 2010·Cancer Letters·Alexander ArltHeiner Schäfer
Dec 29, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·J H StegehuisF A E Kruyt
Apr 23, 2009·Journal of Cellular and Molecular Medicine·Simone Fulda
Jan 22, 2010·International Journal of Cancer. Journal International Du Cancer·Benedetto FarsaciJames W Hodge
Aug 14, 2015·BMC Cancer·Maohua XieXingming Deng
Sep 4, 2010·Expert Opinion on Emerging Drugs·Asfar S AzmiFazlul H Sarkar
Feb 14, 2012·Expert Opinion on Investigational Drugs·Jamal Joudeh, David Claxton
Dec 27, 2011·Expert Opinion on Therapeutic Patents·Naval BajwaZaneta Nikolovska-Coleska
Apr 20, 2010·Molecular Cancer·Susanne SchülerGünter Schneider
Jan 25, 2017·International Journal of Radiation Biology·Qiong WangJing Cheng
Jun 30, 2015·Physical Chemistry Chemical Physics : PCCP·Evangeline DrinkClaire Loison
Jan 1, 2011·Cancers·Simone Fulda
Apr 12, 2013·Experimental Biology and Medicine·Sandra G HudsonPeter J Hahn
Oct 15, 2013·The Journal of Biological Chemistry·Shengbing HuangFrank A Sinicrope

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis